Use of a Safe, Reproducible, and Rapid Aerosol Delivery Method to Study Infection by Burkholderia pseudomallei and Burkholderia mallei in Mice

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Lafontaine, Eric R ^a   Zimmerman, Shawn M ^a   Shaffer, Teresa L ^a   Michel, Frank ^a   Gao, Xiudan ^a   Hogan, Robert J ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE DISEASE; AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTEREMIA; BACTERIAL STRAIN; BAGG ALBINO MOUSE; BIOLOGICAL WARFARE AGENT; BLOOD; BURKHOLDERIA MALLEI; BURKHOLDERIA PSEUDOMALLEI; DOSE RESPONSE; ESCHERICHIA COLI; EXPERIMENTAL MODEL; FEMALE; GLANDERS; GROWTH REGULATION; IMMUNE RESPONSE; INHALATION; INOCULATION; LUNG; MELIOIDOSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PNEUMONIA; REPRODUCIBILITY; SAFETY; SPLEEN;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; ANTIBODIES, BACTERIAL; BACTEREMIA; BIOLOGICAL WARFARE AGENTS; BURKHOLDERIA MALLEI; BURKHOLDERIA PSEUDOMALLEI; DISEASE MODELS, ANIMAL; FEMALE; GLANDERS; HORSES; HUMANS; LUNG; MELIOIDOSIS; MICE; MICE, INBRED BALB C; SPLEEN;

EID: 84884886889     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076804     Document Type: Article

References (90)

1. Cheng AC, Currie BJ, (2005) Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev 18: 383-416. doi:10.1128/CMR.18.2.383-416.2005. PubMed: 15831829.
2. Wiersinga WJ, van der Poll T, White NJ, Day NP, Peacock SJ, (2006) Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nat Rev Microbiol 4: 272-282. doi:10.1038/nrmicro1385. PubMed: 16541135.
3. Adler NR, Govan B, Cullinane M, Harper M, Adler B, et al. (2009) The molecular and cellular basis of pathogenesis in melioidosis: how does Burkholderia pseudomallei cause disease? FEMS Microbiol Rev 33: 1079-1099. doi:10.1111/j.1574-6976.2009.00189.x. PubMed: 19732156.
4. Currie BJ, Fisher DA, Anstey NM, Jacups SP, (2000) Melioidosis: acute and chronic disease, relapse and re-activation. Trans R Soc Trop Med Hyg 94: 301-304. doi:10.1016/S0035-9203(00)90333-X. PubMed: 10975006.
5. Currie BJ, Fisher DA, Howard DM, Burrow JN, Lo D, et al. (2000) Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. Clin Infect Dis 31: 981-986. doi:10.1086/318116. PubMed: 11049780.
6. Wiersinga WJ, van der Poll T, (2009) Immunity to Burkholderia pseudomallei. Curr Opin Infect Dis 22: 102-108. doi:10.1097/QCO.0b013e328322e727. PubMed: 19276877.
7. Vietri NJ, Deshazer D, (2007) Melioidosis. Medical Aspects of Biological Warfare. U.S Army Medical Department Borden Institute Textbooks of Biological Warfare. pp. 147-166.
8. Bondi SK, Goldberg JB, (2008) Strategies toward vaccines against Burkholderia mallei and Burkholderia pseudomallei. Expert Rev Vaccines 7: 1357-1365. doi:10.1586/14760584.7.9.1357. PubMed: 18980539.
9. Galyov EE, Brett PJ, Deshazer D, (2010) Molecular Insights into Burkholderia pseudomallei and Burkholderia mallei Pathogenesis. Annu Rev Microbiol 64: 495-517. doi:10.1146/annurev.micro.112408.134030. PubMed: 20528691.
10. White NJ, (2003) Melioidosis. Lancet 361: 1715-1722. doi:10.1016/S0140-6736(03)13374-0. PubMed: 12767750.
11. Lipsitz R, Garges S, Aurigemma R, Baccam P, Blaney DD, et al. (2012) Workshop on Treatment of and Postexposure Prophylaxis for Burkholderia pseudomallei and B. mallei infection, 2010. Emerg Infect Dis 18. Online report.
12. Dance DA, (2000) Melioidosis as an emerging global problem. Acta Trop 74: 115-119. doi:10.1016/S0001-706X(99)00059-5. PubMed: 10674638.
13. Rolim DB, Vilar DC, Sousa AQ, Miralles IS, de Oliveira DC, et al. (2005) Melioidosis, northeastern Brazil. Emerg Infect Dis 11: 1458-1460. doi:10.3201/eid1109.050493. PubMed: 16229782.
14. Wiersinga WJ, Currie BJ, Peacock SJ, (2012) Melioidosis. N Engl J Med 367: 1035-1044. doi:10.1056/NEJMra1204699. PubMed: 22970946.
15. Arun S, Neubauer H, Gürel A, Ayyildiz G, Kusçu B, et al. (1999) Equine glanders in Turkey. Vet Rec 144: 255-258. doi:10.1136/vr.144.10.255. PubMed: 10209817.
16. Neubauer H, Meyer H, Finke EJ, (1997) Human glanders. Rev Int Serv Sante Forces Armees 70: 258-265.
17. Whitlock GC, Estes DM, Torres AG, (2007) Glanders: off to the races with Burkholderia mallei. FEMS Microbiol Lett 277: 115-122. doi:10.1111/j.1574-6968.2007.00949.x. PubMed: 18031330.
18. Srinivasan A, Kraus CN, DeShazer D, Becker PM, Dick JD, et al. (2001) Glanders in a military research microbiologist. N Engl J Med 345: 256-258. doi:10.1056/NEJM200107263450404. PubMed: 11474663.
19. Waag DM, Deshazer D, (2004) Glanders: New insights into an old disease. In: Lindler LE, Lebeda FJ, Korch GW, eds. Biological Weapons Defense: Infectious Diseases and Counterbioterrorism. Totowa, NJ: Humana Press Inc.
20. Gregory BC, Waag DM, (2007) Glanders. Medical Aspects of Biological Warfare. U.S Army Medical Department Borden Institute Textbooks of Biological Warfare. pp. 121-146.
21. Carr-Gregory B, Waag DM, (2007) Glanders. In: Dembek ZF, eds. Medical Aspects of Biological Warfare: Borden Institute, Office of the Surgeon General. AMEDD Center and School. pp. pp. 121-146.
22. Howe C, (1950) Glanders. In: Christian HA, eds. The Oxford Medicine. New York, NY.: Oxford University Press. pp. pp. 185-202.
23. Thibault FM, Hernandez E, Vidal DR, Girardet M, Cavallo JD, (2004) Antibiotic susceptibility of 65 isolates of Burkholderia pseudomallei and Burkholderia mallei to 35 antimicrobial agents. J Antimicrob Chemother 54: 1134-1138. doi:10.1093/jac/dkh471. PubMed: 15509614.
24. Viktorov DV, Zakharova IB, Podshivalova MV, Kalinkina EV, Merinova OA, et al. (2008) High-level resistance to fluoroquinolones and cephalosporins in Burkholderia pseudomallei and closely related species. Trans R Soc Trop Med Hyg 102 (Suppl 1) ():: S103-S110. doi:10.1016/S0035-9203(08)70025-7. PubMed: 19121669.
25. Alibek K, Handelman S, (1999) Biohazard: the chilling true story of the largest covert biological weapons program in the world. New York: Random House.
26. Lehavi O, Aizenstien O, Katz LH, Hourvitz A, (2002) [Glanders--a potential disease for biological warfare in humans and animals]. Harefuah 141Spec No 88-91: 119.
27. Wheelis M, (1999) Biological sabotage in World War I. Geissler E, Moon JEvC, eds. Biological and toxin weapons: research, development, and use from the Middle Ages to 1945. Oxford: Oxford University Press. pp. pp. 35-72.
28. Wheelis M, (1998) First shots fired in biological warfare. Nature 395: 213. doi:10.1038/26091. PubMed: 9751039.
29. Smart JK, (1997) History of chemical and biological warfare: an American perspective. In: Zajtchuk R, Bellarmy RF, eds. Textbook of Military Medicine Borden Institute and Office of the Army Surgeon General. pp. pp. 16-64.
30. Regis E, (1999) The biology of doom. New York: Henry Holt and Company.
31. Kortepeter M, Christopher G, Cieslak T, et al. (2001) USAMRIID's Medical Managementof Biological Casualties Handbook. 4th ed. Frederick, MD, US Army Medical Research Institute of Infectious Diseases. pp. pp. 44-52.
32. Shoham D, (1998) Cemical and biological weapons in Egypt. Nonproliferation Rev 5: 48-58. doi:10.1080/10736709808436720.
33. Warawa JM, (2010) Evaluation of surrogate animal models of melioidosis. Front Microbiol 1: 141. PubMed: 21772830.
34. Titball RW, Russell P, Cuccui J, Easton A, Haque A, et al. (2008) Burkholderia pseudomallei: animal models of infection. Trans R Soc Trop Med Hyg 102 (Suppl 1) ():: S111-S116. doi:10.1016/S0035-9203(08)70026-9. PubMed: 19121670.
35. Judy BM, Whitlock GC, Torres AG, Estes DM, (2009) Comparison of the in vitro and in vivo susceptibilities of Burkholderia mallei to Ceftazidime and Levofloxacin. BMC Microbiol 9: 88. doi:10.1186/1471-2180-9-88. PubMed: 19426516.
36. Whitlock GC, Valbuena GA, Popov VL, Judy BM, Estes DM, et al. (2009) Burkholderia mallei cellular interactions in a respiratory cell model. J Med Microbiol 58: 554-562. doi:10.1099/jmm.0.007724-0. PubMed: 19369515.
37. Massey S, Johnston K, Mott TM, Judy BM, Kvitko BH, et al. (2011) In vivo Bioluminescence Imaging of Burkholderia mallei Respiratory Infection and Treatment in the Mouse Model. Front Microbiol 2: 174. PubMed: 21904535.
38. Goodyear A, Troyer R, Bielefeldt-Ohmann H, Dow S, (2012) MyD88-dependent recruitment of monocytes and dendritic cells required for protection from pulmonary Burkholderia mallei infection. Infect Immun 80: 110-120. doi:10.1128/IAI.05819-11. PubMed: 22025508.
39. Goodyear A, Kellihan L, Bielefeldt-Ohmann H, Troyer R, Propst K, et al. (2009) Protection from pneumonic infection with Burkholderia species by inhalational immunotherapy. Infect Immun 77: 1579-1588. doi:10.1128/IAI.01384-08. PubMed: 19179415.
40. Goodyear A, Jones A, Troyer R, Bielefeldt-Ohmann H, Dow S, (2010) Critical protective role for MCP-1 in pneumonic Burkholderia mallei infection. J Immunol 184: 1445-1454. doi:10.4049/jimmunol.0900411. PubMed: 20042590.
41. Atoynatan T, Hsiung GD, (1969) Epidemiologic studies of latent virus infections in captive monkeys and baboons. II. Serologic evidence of myxovirus infections with special reference to SV5. Am J Epidemiol 89: 472-479. PubMed: 4305202.
42. Harkema JR, Carey SA, Wagner JG, (2006) The nose revisited: a brief review of the comparative structure, function, and toxicologic pathology of the nasal epithelium. Toxicol Pathol 34: 252-269. doi:10.1080/01926230600713475. PubMed: 16698724.
43. Munder A, Krusch S, Tschernig T, Dorsch M, Lührmann A, et al. (2002) Pulmonary microbial infection in mice: comparison of different application methods and correlation of bacterial numbers and histopathology. Exp Toxicol Pathol 54: 127-133. doi:10.1078/0940-2993-00240. PubMed: 12211633.
44. Su X, Looney M, Robriquet L, Fang X, Matthay MA, (2004) Direct visual instillation as a method for efficient delivery of fluid into the distal airspaces of anesthetized mice. Exp Lung Res 30: 479-493. doi:10.1080/01902140490476382. PubMed: 15524406.
45. Warawa JM, Long D, Rosenke R, Gardner D, Gherardini FC, (2011) Bioluminescent diagnostic imaging to characterize altered respiratory tract colonization by the burkholderia pseudomallei capsule mutant. Front Microbiol 2: 133. PubMed: 21720539.
46. Owen SJ, Batzloff M, Chehrehasa F, Meedeniya A, Casart Y, et al. (2009) Nasal-associated lymphoid tissue and olfactory epithelium as portals of entry for Burkholderia pseudomallei in murine melioidosis. J Infect Dis 199: 1761-1770. doi:10.1086/599210. PubMed: 19456230.
47. Lever MS, Nelson M, Ireland PI, Stagg AJ, Beedham RJ, et al. (2003) Experimental aerogenic Burkholderia mallei (glanders) infection in the BALB/c mouse. J Med Microbiol 52: 1109-1115. doi:10.1099/jmm.0.05180-0. PubMed: 14614070.
48. Tan GY, Liu Y, Sivalingam SP, Sim SH, Wang D, et al. (2008) Burkholderia pseudomallei aerosol infection results in differential inflammatory responses in BALB/c and C57Bl/6 mice. J Med Microbiol 57: 508-515. doi:10.1099/jmm.0.47596-0. PubMed: 18349373.
49. Lever MS, Nelson M, Stagg AJ, Beedham RJ, Simpson AJ, (2009) Experimental acute respiratory Burkholderia pseudomallei infection in BALB/c mice. Int J Exp Pathol 90: 16-25. doi:10.1111/j.1365-2613.2008.00619.x. PubMed: 19200247.
50. Jeddeloh JA, Fritz DL, Waag DM, Hartings JM, Andrews GP, (2003) Biodefense-driven murine model of pneumonic melioidosis. Infect Immun 71: 584-587. doi:10.1128/IAI.71.1.584-587.2003. PubMed: 12496217.
51. Barnes KB, Steward J, Thwaite JE, Lever MS, Davies CH, et al. (2013) Trimethoprim/sulfamethoxazole (co-trimoxazole) prophylaxis is effective against acute murine inhalational melioidosis and glanders. Int J Antimicrob Agents 41: 552-557. PubMed: 23517714.
52. Majerczyk C, Kinman L, Han T, Bunt R, Greenberg EP, (2013) Virulence of Burkholderia mallei Quorum-Sensing Mutants. Infect Immun 81: 1471-1478. doi:10.1128/IAI.00048-13. PubMed: 23429539.
53. DeShazer D, Brett PJ, Carlyon R, Woods DE, (1997) Mutagenesis of Burkholderia pseudomallei with Tn5-OT182: isolation of motility mutants and molecular characterization of the flagellin structural gene. J Bacteriol 179: 2116-2125. PubMed: 9079894.
54. Nierman WC, DeShazer D, Kim HS, Tettelin H, Nelson KE, et al. (2004) Structural flexibility in the Burkholderia mallei genome. Proc Natl Acad Sci U S A 101: 14246-14251. doi:10.1073/pnas.0403306101. PubMed: 15377793.
55. Reed LJ, Muench H, (1938) A simple method for estimating fifty percent end points. Am J Hyg 27: 793-497.
56. Balder R, Lipski S, Lazarus JJ, Grose W, Wooten RM, et al. (2010) Identification of Burkholderia mallei and Burkholderia pseudomallei adhesins for human respiratory epithelial cells. BMC Microbiol 10: 250. doi:10.1186/1471-2180-10-250. PubMed: 20920184.
57. Sambrook J, Russell DW, (2001) Molecular Cloning: A Laboratory Manual (Third Edition). Cold Spring Harbor Laboratory Press.
58. Holden MT, Titball RW, Peacock SJ, Cerdeño-Tárraga AM, Atkins T, et al. (2004) Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc Natl Acad Sci U S A 101: 14240-14245. doi:10.1073/pnas.0403302101. PubMed: 15377794.
59. Balder R, Hassel J, Lipski S, Lafontaine ER, (2007) Moraxella catarrhalis strain O35E expresses two filamentous hemagglutinin-like proteins that mediate adherence to human epithelial cells. Infect Immun 75: 2765-2775. doi:10.1128/IAI.00079-07. PubMed: 17371858.
60. Lipski SL, Akimana C, Timpe JM, Wooten RM, Lafontaine ER, (2007) The Moraxella catarrhalis Autotransporter McaP Is a Conserved Surface Protein That Mediates Adherence to Human Epithelial Cells through Its N-Terminal Passenger Domain. Infect Immun 75: 314-324. doi:10.1128/IAI.01330-06. PubMed: 17088358.
61. Reckseidler SL, DeShazer D, Sokol PA, Woods DE, (2001) Detection of bacterial virulence genes by subtractive hybridization: identification of capsular polysaccharide of Burkholderia pseudomallei as a major virulence determinant. Infect Immun 69: 34-44. doi:10.1128/IAI.69.1.34-44.2001. PubMed: 11119486.
62. Burtnick MN, Woods DE, (1999) Isolation of polymyxin B-susceptible mutants of Burkholderia pseudomallei and molecular characterization of genetic loci involved in polymyxin B resistance. Antimicrob Agents Chemother 43: 2648-2656. PubMed: 10543742.
63. Bivas-Benita M, Zwier R, Junginger HE, Borchard G, (2005) Non-invasive pulmonary aerosol delivery in mice by the endotracheal route. Eur J Pharm Biopharm 61: 214-218. doi:10.1016/j.ejpb.2005.04.009. PubMed: 16039104.
64. Song H, Hwang J, Yi H, Ulrich RL, Yu Y, et al. (2010) The early stage of bacterial genome-reductive evolution in the host. PLOS Pathog 6: e1000922. PubMed: 20523904.
65. Cowell R, Tyler R, (2002) Diagnostic Cytology and Hematology of the Horse, Second Edition. St-Louis: Mosby Inc. p. pp. 70.
66. Cowell R, Tyler R, Meinkoth J, DeNicola D, (2008) Diagnostic Cytology and Hematology of the Dog and Cat, Third Edition. St-Louis: Mosby Inc. pp. pp. 238-239.
67. Peyron P, Maridonneau-Parini I, Stegmann T, (2001) Fusion of human neutrophil phagosomes with lysosomes in vitro: involvement of tyrosine kinases of the Src family and inhibition by mycobacteria. J Biol Chem 276: 35512-35517. doi:10.1074/jbc.M104399200. PubMed: 11463789.
68. Weiss D, Wardrop K, (2010) Schalm's Veterinary Hematology, Sixth Edition. Ames: Blackwell Publishing. p. pp. 270.
69. DeShazer D, Brett PJ, Woods DE, (1998) The type II O-antigenic polysaccharide moiety of Burkholderia pseudomallei lipopolysaccharide is required for serum resistance and virulence. Mol Microbiol 30: 1081-1100. doi:10.1046/j.1365-2958.1998.01139.x. PubMed: 9988483.
70. DeShazer D, Waag DM, Fritz DL, Woods DE, (2001) Identification of a Burkholderia mallei polysaccharide gene cluster by subtractive hybridization and demonstration that the encoded capsule is an essential virulence determinant. Microb Pathog 30: 253-269. doi:10.1006/mpat.2000.0430. PubMed: 11373120.
71. Ulrich RL, Amemiya K, Waag DM, Roy CJ, DeShazer D, (2005) Aerogenic vaccination with a Burkholderia mallei auxotroph protects against aerosol-initiated glanders in mice. Vaccine 23: 1986-1992. doi:10.1016/j.vaccine.2004.10.017. PubMed: 15734072.
72. Sim BM, Chantratita N, Ooi WF, Nandi T, Tewhey R, et al. (2010) Genomic acquisition of a capsular polysaccharide virulence cluster by non-pathogenic Burkholderia isolates. Genome Biol 11: R89. doi:10.1186/gb-2010-11-8-r89. PubMed: 20799932.
73. Burtnick MN, Heiss C, Roberts RA, Schweizer HP, Azadi P, et al. (2012) Development of capsular polysaccharide-based glycoconjugates for immunization against melioidosis and glanders. Front Cell Infect Microbiol 2: 108. PubMed: 22912938.
74. Anuntagool N, Sirisinha S, (2002) Antigenic relatedness between Burkholderia pseudomallei and Burkholderia mallei. Microbiol Immunol 46: 143-150. PubMed: 12008922.
75. Zou N, Tsai S, Feng SH, Newsome T, Kim HY, et al. (2008) Relationship between antigenicity and pathogenicity for Burkholderia pseudomallei and Burkholderia mallei revealed by a large panel of mouse MAbs. Hybridoma (Larchmt) 27: 231-240. doi:10.1089/hyb.2008.0012. PubMed: 18707541.
76. Bryan LE, Wong S, Woods DE, Dance DA, Chaowagul W, (1994) Passive protection of diabetic rats with antisera specific for the polysaccharide portion of the lipopolysaccharide isolated from Pseudomonas pseudomallei. Can J Infect Dis 5: 170-178. PubMed: 22346496.
77. Knirel YA, Paramonov NA, Shashkov AS, Kochetkov NK, Yarullin RG, et al. (1992) Structure of the polysaccharide chains of Pseudomonas pseudomallei lipopolysaccharides. Carbohydr Res 233: 185-193. doi:10.1016/S0008-6215(00)90930-3. PubMed: 1280183.
78. Perry MB, MacLean LL, Schollaardt T, Bryan LE, Ho M, (1995) Structural characterization of the lipopolysaccharide O antigens of Burkholderia pseudomallei. Infect Immun 63: 3348-3352. PubMed: 7543882.
79. Parthasarathy N, DeShazer D, England M, Waag DM, (2006) Polysaccharide microarray technology for the detection of Burkholderia pseudomallei and Burkholderia mallei antibodies. Diagn Microbiol Infect Dis 56: 329-332. doi:10.1016/j.diagmicrobio.2006.04.018. PubMed: 16765554.
80. Parthasarathy N, Saksena R, Kováč P, Deshazer D, Peacock SJ, et al. (2008) Application of carbohydrate microarray technology for the detection of Burkholderia pseudomallei, Bacillus anthracis and Francisella tularensis antibodies. Carbohydr Res 343: 2783-2788. doi:10.1016/j.carres.2008.05.021. PubMed: 18558401.
81. Ho M, Schollaardt T, Smith MD, Perry MB, Brett PJ, et al. (1997) Specificity and functional activity of anti-Burkholderia pseudomallei polysaccharide antibodies. Infect Immun 65: 3648-3653. PubMed: 9284132.
82. Parthasarathy N, Deshazer D, Peacock S, Wuthiekanun V, England M, et al. (2008) Application of Polysaccharide Microarray Technology for the Serodiagnosis of Burkholderia pseudomallei Infection (Melioidosis) in Humans. J Carbohydr Chem 27: 32-40. doi:10.1080/07328300802030761.
83. Tiyawisutsri R, Holden MT, Tumapa S, Rengpipat S, Clarke SR, et al. (2007) Burkholderia Hep_Hap autotransporter (BuHA) proteins elicit a strong antibody response during experimental glanders but not human melioidosis. BMC Microbiol 7: 19. doi:10.1186/1471-2180-7-19. PubMed: 17362501.
84. Felgner PL, Kayala MA, Vigil A, Burk C, Nakajima-Sasaki R, et al. (2009) A Burkholderia pseudomallei protein microarray reveals serodiagnostic and cross-reactive antigens. Proc Natl Acad Sci U S A 106: 13499-13504. doi:10.1073/pnas.0812080106. PubMed: 19666533.
85. Chandenier J, Bernard S, Montharu J, Bailly E, Fetissof F, et al. (2009) The utility of a nebulised intra-tracheal rat model of invasive pulmonary aspergillosis. Mycoses 52: 239-245. doi:10.1111/j.1439-0507.2009.01695.x. PubMed: 19383006.
86. Goff AJ, Chapman J, Foster C, Wlazlowski C, Shamblin J, et al. (2011) A novel respiratory model of infection with monkeypox virus in cynomolgus macaques. J Virol 85: 4898-4909. doi:10.1128/JVI.02525-10. PubMed: 21389129.
87. Funk CJ, Manzer R, Miura TA, Groshong SD, Ito Y, et al. (2009) Rat respiratory coronavirus infection: replication in airway and alveolar epithelial cells and the innate immune response. J Gen Virol 90: 2956-2964. doi:10.1099/vir.0.014282-0. PubMed: 19741068.
88. Andreu N, Zelmer A, Fletcher T, Elkington PT, Ward TH, et al. (2010) Optimisation of bioluminescent reporters for use with mycobacteria. PLOS ONE 5: e10777. doi:10.1371/journal.pone.0010777. PubMed: 20520722.
89. Prakash H, Albrecht M, Becker D, Kuhlmann T, Rudel T, (2010) Deficiency of XIAP leads to sensitization for Chlamydophila pneumoniae pulmonary infection and dysregulation of innate immune response in mice. J Biol Chem 285: 20291-20302. doi:10.1074/jbc.M109.096297. PubMed: 20427267.
90. Revelli DA, Boylan JA, Gherardini FC, (2012) A non-invasive intratracheal inoculation method for the study of pulmonary melioidosis. Front Cell Infect Microbiol 2: 164. PubMed: 23267442.